Dexmedetomidine on Microcirculation in Septic Shock

Phase 4

Completed

• Conditions: Septic Shock
• Interventions: Drug: Dexmedetomidine 0.7 Mcg/kg/h

• Registration Number: NCT02270281
• Lead Sponsor: Southeast University, China

Brief Summary

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Detailed Description

Septic shock is characterized by significant decline in vascular response and relative hypovolemia. Fluids and exogenous catecholamines are mainstay. However, even after initial resuscitation, microcirculatory dysfunctions still exist, and represent a direct physiologic link to organ failure and death. Therefore, therapeutic strategies aiming at improving microcirculation are performed.

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Based on the hypothesis that dexmedetomidine might improve microcirculation in initial resuscitated septic shock patients, the study was to investigate the effects of dexmedetomidine on microcirculation in early septic shock patients despite initial resuscitation. Meanwhile, to observe the possible mechanism of the effect, the correlation between dexmedetomidine dose and microcirculatory parameters as well as catecholamine level were performed.

Study Timeline

• Study First Submitted: 2014-10-16
• Study First Submitted QC: 2014-10-20
• Study First Posted: 2014-10-21
• Study Start: 2014-12
• Primary Completion: 2016-12
• Study Completion: 2017-05
• Status Verified: 2018-12
• Last Update Submitted: 2018-12-10
• Last Update Posted: 2018-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dexmedetomidine	Dexmedetomidine 0.7 Mcg/kg/h	Before dexmedetomidine infusion

Primary Outcome Measures

Name	Time	Method
Perfused vascular density	One hour	Perfused vascular density was calculated by multiplying vessel density by the proportion of perfused vessels

Secondary Outcome Measures

Name	Time	Method
Total vascular density	One hour	Vascular density was calculated by the number of vessels crossing these lines
Microcirculatory flow index	One hour	Based on the major type of flow in all quadrants were determined with a semi-quantitative methodology

Trial Locations

Locations (1)

Zhongda Hospital Southeast University; 🇨🇳 Nanjing, Jiangsu, China